To compensate for the lack of CD7, they used gene-editing technology to add CD132 to the CAR T-cells to increase the production of IL-2 (49), which enhanced the proliferation and anti-tumor efficacy of the CAR T-cells (cell line: Jurkat; animal model: NSG mice). The gene discussed is CD7; the disease is neoplasm.